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Aging is associated with the accumulation of various deleterious changes in cells.
According to the free radical and mitochondrial theory of aging, mitochondria initiate most
of the deleterious changes in aging and govern life span. The failure of mitochondrial
reduction-oxidation (redox) homeostasis and the formation of excessive free radicals
are tightly linked to dysregulation in the Renin Angiotensin System (RAS). A main
rate-controlling step in RAS is renin, an enzyme that hydrolyzes angiotensinogen to
generate angiotensin I. Angiotensin I is further converted to Angiotensin II (Ang II)
by angiotensin-converting enzyme (ACE). Ang II binds with equal affinity to two main
angiotensin receptors—type 1 (AT1R) and type 2 (AT2R). The binding of Ang II to AT1R
activates NADPH oxidase, which leads to increased generation of cytoplasmic reactive
oxygen species (ROS). This Ang II-AT1R–NADPH-ROS signal triggers the opening of
mitochondrial KATP channels and mitochondrial ROS production in a positive feedback
loop. Furthermore, RAS has been implicated in the decrease of many of ROS scavenging
enzymes, thereby leading to detrimental levels of free radicals in the cell. AT2R is
less understood, but evidence supports an anti-oxidative and mitochondria-protective
function for AT2R. The overlap between age related changes in RAS and mitochondria,
and the consequences of this overlap on age-related diseases are quite complex. RAS
dysregulation has been implicated in many pathological conditions due to its contribution
to mitochondrial dysfunction. Decreased age-related, renal and cardiac mitochondrial
dysfunction was seen in patients treated with angiotensin receptor blockers. The aim of
this review is to: (a) report the most recent information elucidating the role of RAS in
mitochondrial redox hemostasis and (b) discuss the effect of age-related activation of RAS
on generation of free radicals.
Keywords: mitochondria, angiotensin II, angiotensin II type 1 receptor blockers, mitochondrial angiotensin system,
redox regulation, aging, frailty
MITOCHONDRIA AND ANGIOTENSIN SYSTEM: OVERVIEW
It is well accepted that mitochondria are the major source of
ATP, which is the fuel for many cellular processes. However,
mitochondrial function extends well beyond bioenergetics (Kang
and Pervaiz, 2012). Accumulating evidence suggests that mito-
chondria are also signaling organelles that interact with the rest
of the cell through ROS and an array of other signaling com-
plexes (Shigenaga et al., 1994; Turrens, 2003; Chandel, 2014).
Earlier studies suggested that mitochondrial ROS were detrimen-
tal byproducts associated with several pathological conditions
(Turrens, 2003; Chandel, 2014). However, more recent studies
suggest that ROS may have fundamental cellular functions—
acting as signaling molecules (Chandel, 2014), stabilizing hypoxia
inducible factors (HIFs), and inducing gene expression to pro-
mote cellular adaptation to low oxygen levels (Chandel et al.,
1998, 2000a). ROS also play a role in tumor necrosis factor (TNF)
receptor signaling (Chandel et al., 2000b, 2001; Nemoto et al.,
2000; Chandel, 2014) and defense against pathogens (Yu et al.,
2012).
RAS is a key hormonal pathway that affects virtually every
organ.While many of the endocrine (circulating), paracrine (cell-
to-different cell), and autocrine (cell-to-same cell) effects of the
RAS are believed to bemediated through the canonical extracellu-
lar RAS, an independent and differentially regulated intracellular
RAS has also been proposed (Robertson and Khairallah, 1971;
Inagami et al., 1986, 1988, 1990; Hunt et al., 1992; Sadoshima
et al., 1993; Mercure et al., 1998; Vila-Porcile and Corvol, 1998;
Cook et al., 2001; Sherrod et al., 2005; Kumar et al., 2007, 2008,
2012; Peters, 2008, 2012; Abadir et al., 2011, 2012). The major
components of RAS are (1) angiotensinogen, derived from the
liver; (2) renin, derived from the juxtaglomerular cells of afferent
arterioles; (3) angiotensin converting enzyme (ACE), a dipep-
tidyl carboxypeptidase; (4) angiotensin II, and (5) angiotensin II
receptors. Angiotensinogen is a globular protein that serves as a
substrate for renin, a glycoproteolytic enzyme. The first step of
the RAS pathway is conversion of angiotensinogen to angiotensin
I by renin. Angiotensin I is then converted to angiotensin II via
ACE enzyme (Griendling et al., 1993). At all levels -endocrine,
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paracrine, and autocrine—Ang II binds to twomain receptor sub-
types, AT1R and AT2R. Both belong to the G-protein-coupled
receptor family but differ in terms of tissue distribution and
cell signaling pathways. Ang II binds with equal affinity to
AT1R and AT2R. These receptors, in turn, activate multiple sig-
nal transduction pathways that include signaling molecules like
Nitric Oxide (NO·), Protein Tyrosine Phosphatases (PTP), and
Mitogen-activated protein kinase (MAPK) (Abadir, 2011; Abadir
et al., 2012). AT1R and AT2R stimulation generally leads to oppos-
ing actions (Abadir, 2011; Abadir et al., 2012) summarized in
Table 1.
Evidence supporting an important role for RAS in mito-
chondrial function/dysfunction comes from many sources (Cook
and Re, 2012; Ellis et al., 2012; Garcia et al., 2012; Gwathmey
et al., 2012; Li et al., 2012; Singh et al., 2012; Wangler et al.,
2012; Yu et al., 2012; Zaobornyj and Ghafourifar, 2012; Ferder
et al., 2013; Sovari et al., 2013). The main function of mito-
chondria is to generate ATP via the electron transport chain.
Electrons are transferred through complex I to complex IV
with oxygen as the final electron acceptor. Damaged ETC com-
plexes may no longer accept electrons, leading to generation of
ROS (Kregel and Zhang, 2007). AT1R knock-out mice exhibit a
notable phenotype with increased mitochondrial numbers and
average lifespan extension exceeding 25% (Benigni et al., 2009).
Other clues of the influence of RAS on mitochondria may be
gleaned from prior work, which demonstrated that Ang II infu-
sion in rodents induced cardiomyopathy by increasing mito-
chondrial ROS generation. In these animals, overexpression of
catalase specific for mitochondria, but not peroxisomes, pro-
tected them against cardiac hypertrophy, fibrosis, and diastolic
dysfunction (Dai et al., 2009; Dikalov and Nazarewicz, 2013).
The recent identification of a functional intra-mitochondrial
angiotensin system (MAS) provided additional insight into the
RAS interface with mitochondria (Eto et al., 2002; Kumar et al.,
2008; Abadir et al., 2011, 2012). Recently, changes in MAS and
a novel role for AT1R on mitochondrial respiration in dia-
betes were reported (Persson et al., in press). In mitochondria
from renal tubular cells, expression of AT2R decreases while
AT1R increases with age. Chronic administration of losartan,
an angiotensin receptor blocker, prevented age-related decrease
of mitochondrial AT2R. Other parts of the system including
renin and ACE have also been localized intracellularly, with
evidence suggesting their presence in the nucleus and mito-
chondria (Vidotti et al., 2004; Abadir et al., 2012). Interestingly,
this intracellular system is independent of circulating RAS; ACE
Table 1 | Opposing functions of AT1R and AT2R.
AT1R AT2R
Vasoconstriction Vasodilation
↑ cell growth ↓ cell growth
Cellular proliferation Cellular differentiation
Anti-naturetic Naturetic
Production of O2 Production of NO
↑ fibroblast proliferation/collagen synthesis ↓ fibroblast proliferation
Pro-apoptotic Anti-apoptotic
inhibitors fail to block intracellular ACE (Cristovam et al.,
2008).
Several groups demonstrated a tight link between RAS,
mitochondria, and a host of age-related pathologic conditions
(Inagami, 2011; Carey, 2012; Conti et al., 2012; Cook and Re,
2012; Dai et al., 2012; Ellis et al., 2012; Gao et al., 2012; Garcia
et al., 2012; Gwathmey et al., 2012; Horan et al., 2012; Li et al.,
2012; Singh et al., 2012; Wangler et al., 2012; Yu et al., 2012;
Zaobornyj and Ghafourifar, 2012). In addition, RAS dysregula-
tion aggravates several acute and chronic diseases, many of which
have been linked to mitochondrial dysfunction [atherosclerosis
(Warnholtz et al., 1999), kidney disease (Ma et al., 1998), myocar-
dial damage after infarction (Kuno et al., 2002), cerebral infarct
size after ischemia (Panahpour and Dehghani, 2012)]. Locally
activated RAS in heart tissue has been implicated in cardiac
hypertrophy and fibrosis (Kumar et al., 2008). The mechanism by
which intracellular angiotensin II (iAng II) affects cardiac tissue
has been a topic of debate for years. One possible mechanism is
that iAng II interacts with intracellular AT1R or AT1-like recep-
tors to bring about the observed changes. Another mechanism
involves iAng II binding directly to chromatin to promote the
transcription of growth factors like insulin, PDGF, and FGF-2
(Baker et al., 2004). iAng II may also may also affect Ca+2 fluxes
and activate phospholipase C and PKC by binding to AT1R on
sarcolemma, mitochondria, or internalized receptors (Eto et al.,
2002; Baker et al., 2004).
Similar to extracellular RAS, intracellular RAS has been impli-
cated inmany pathological conditions as well. Intracellularly, RAS
is highly active in producing increased amounts of iAng II in mice
with advanced heart failure. Increased ventricular hypertrophy
or fibrosis was also observed (De Mello and Gerena, 2008). The
mechanism by which Ang II is produced has not been defined yet.
Pressure overload and mechanical stretch of cardiomyocytes after
myocardial infarction may cause secretion of local Ang II. After
examination of levels of expression of angiotensinogen, renin,
ACE and AT1 genes, stretched cardiac myocytes were observed
to have higher levels of mRNA and RAS enzymes than un-
stretched myocytes (Malhotra et al., 1999). This increased Ang
II seems to work through a mineralocorticoid receptor because
the administration of an aldosterone receptor antagonist mit-
igated the effect of Ang II on inward Ca+2 current in failing
hearts (De Mello and Gerena, 2008). Ang II further caused cell
swelling in failing cardiac myocytes via activation of ionic chan-
nels and decrease in gap junction permeability. These molecular
changes may lead to altered gene expression, which could be con-
tributing to cardiac remodeling. In addition, changes in ionic and
gap junction permeability can decrease action potential duration
and conduction velocity. All of these factors may lead to cardiac
arrhythmias by causing electrical uncoupling, mechanical de-
synchronization, and cardiac remodeling (DeMello and Frohlich,
2011). Furthermore, diabetic patients seem to have upregulated
intracellular RAS activity because high glucose in rat mesangial
cells resulted in ∼30-fold increase in intracellular renin (iRenin)
activity and increased iAng II concentrations localized mostly
to the nucleus. Localization of iAng II to the nucleus suggests
that the mechanism of action of iAng II is both cytoplasmic and
nuclear. Renin and chymase (an alternative Ang II-generating
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enzyme), were implicated in the glucose-induced increase in Ang
II rather than ACE; this confirms that the increased Ang II is
not due to increased uptake of circulating Ang II but rather due
to localized tissue synthesis (Re et al., 1984; Vidotti et al., 2004;
Kumar et al., 2007).
MITOCHONDRIAL REDUCTION-OXIDATION (REDOX)
BALANCE: ROLE OF RAS IN ROS GENERATION, TRANSPORT
AND ELIMINATION
Mitochondria play a critical role in redox chemistry.
Mitochondrial redox balance is the process by which, under
physiological conditions, mitochondria maintain a dynamic
balance between ROS generation, their transport, and an array
of antioxidant systems (glutathione, glutathione peroxidase, glu-
tathione reductase, MnSOD, catalase, and thioredoxin system) in
response to fluctuations in cellular energy demand (Aon et al.,
2010; Cortassa et al., 2014).
ROS GENERATION AND TRANSPORT
ROS are generated from various sources including NADPH oxi-
dase (NOX2 and NOX4), uncoupled nitric oxide synthase (NOS),
xanthine oxidase (XO), and mitochondria. Of these, mitochon-
dria are the main source of ROS (Nickel et al., 2014).
ROS are generated in the respiratory chain, mainly at the
level of complex I and III (Murphy, 2009; Kembro et al., 2014)
although recent evidence also involves complex II (Drose, 2013).
Electron transfer between the respiratory complexes in the
respiratory chain generates a proton motive force composed of
proton and electrical gradients that then drives ATP synthesis
at the level of ATP synthase. NADH and FADH2, generated in
the Tricarboxylic Acid (TCA) cycle act as electron donors for
the electron transport chain (ETC) (Rich and Marechal, 2010).
Oxygen is the final acceptor of four electrons transferred from the
ETC, and converted to H2O (Mitchell, 1961; Liu et al., 2002). If
less than four electrons are transferred to oxygen, ROS are pro-
duced (Kregel and Zhang, 2007). Damaged ETC complexes may
no longer accept electrons. Excess ROS can damage respiratory
complexes and initiate a vicious cycle of ROS overflow thus high-
lighting the fact that mitochondria can be both source and victim
of oxidative stress (Daiber, 2010).
ADP and Ca+2, can modulate the rate of ATP generation
according to energy demand. ADP stimulates ATP synthesis via
F1F0 ATPase, driven mainly by the electrical component of the
proton motive force (Wood, 2006). The dissipation of the mito-
chondrial membrane potential generates a “pull” of electrons
from NADH at the level of complex I, or FADH2 from succinate
at the level of complex II thus increasing O2 consumption.
As a matter of fact, an increase in energy demand, e.g., higher
cardiac workload under exercising conditions, will increase both
ADP and Ca2+ uptake by the mitochondria to increase ATP sup-
ply to match the demand (Cortassa et al., 2006; Murphy, 2009).
Energized mitochondria will exhibit higher levels of ATP and
NAD(P)H and lower electron flow thus increasing the proba-
bility of O·−2 generation in the respiratory chain. Consequently,
mitochondrial ROS production is highly dependent on the ener-
getic and redox status of mitochondria (Kang and Pervaiz, 2012;
Cortassa et al., 2014).
RAS-INDUCED MITOCHONDRIAL ROS GENERATION
As mentioned before, angiotensin II can bind to two major recep-
tors: AT1R and AT2R. Ang II binding to AT1R in the plasma
membrane has been implicated in increased ROS production
(Figure 1). Ang II-AT1R can activate NADPH oxidase, leading
to increased generation of cytoplasmic ROS. This Ang II-AT1R–
NADPH-ROS signal triggers the opening of mitochondrial KATP
(mtKATP) channels (Figure 2) that in turn activates mitochon-
drial ROS production in a positive feedback loop (Daiber, 2010).
Opening of mtKATP channels decreases mitochondrial membrane
potential. This triggers the opening of mitochondrial permeabil-
ity transition (MPT) channel. The loss of membrane potential
due to opening of the inner membrane anion channel (IMAC)
(Aon et al., 2003, 2007) or the permeability transition pore (PTP)
(Zorov et al., 2000) can produce a burst of mitochondrial ROS
leading to ROS-induced ROS release (Zorov et al., 2000; Aon
et al., 2003; Zhang et al., 2007).
MAJOR SITES OF O.−2 GENERATION
(i) Complex I or NADH: ubiquinone oxidoreductase is consid-
ered one of the major source of superoxide production in
the ETC complexes (Brand et al., 2004). Electrons from suc-
cinate can flow in reverse to complex I to reduce NAD+ to
NADH. This reverse electron transfer (RET) increases ROS
production at the level of complex I. When treated with
ADP or malonate, both of which block RET, mitochondrial
ROS emission decreases (Liu et al., 2002). Which compo-
nent of complex I—FMN, Fe-S clusters, or ubiquinone—is
producing superoxide is not clear (Brand et al., 2004). Ang II
has been shown to damage complex I, thus contributing to
FIGURE 1 | Scheme for RAS induced ROS generation. The binding of
Ang II to AT1R activates NADPH oxidase that transfers an electron from
NADPH to O2generating O·−2 . Location and expression level of different
NOX enzymes determine their function. (SOD, Superoxide dismutase;
TrxRD, thioredoxin reductase; GR, Glutathione Reductase; GPX,
Glutathione peroxidase; PRx3, peroxiredoxin 3; TRx2, thioredoxin).
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FIGURE 2 | Scheme for the effects of Ang II on mitochondrial KATP channels. Ang II-AT1R–NADPH-ROS signal triggers the opening of mitochondrial KATP
channels and mitochondrial ROS production in a positive feedback loop.
ROS generation. Specifically, Ang II is able to down-regulate
ND5, a component of complex I, via oxidation of mtDNA
thus decreasing electron flow and the likelihood of ROS
generation (Ricci et al., 2005).
(ii) Cytochrome bc1 complex or complex III is another impor-
tant source of O·−2 generation. Coenzyme Q, or ubiquinol
(QH2), is the electron donor for complex III. Reduced coen-
zyme Q (QH2) diffuses to the inner side of mitochondrial
membrane to the Qo site, where it transfers one electron
to cytochrome c bound to complex III. Cytochrome c then
transfers electrons to complex IV. Another QH2 transfers an
electron to the oxidized coenzymeQ (Q), reducing it to QH2
near the matrix side of the membrane (Qi site) (Quinlan
et al., 2011). After losing an electron to cytochrome c
and prior to transferring an electron to Q, ubiquinol may
form the intermediate ubisemiquinone (Q.). Electrons can
leak (Turrens, 2003) from Q· to oxygen, forming O·−2 .
Antimycin, a Qi site inhibitor, elicits large amounts of O·−2
when O2 reacts with ubisemiquinone bound to the Qo site
(Murphy, 2009). Under normal conditions, O·−2 generation
from complex I and III varies according to tissue condi-
tions. . . . For example, complex III appears to be the primary
source of O·−2 in heart and lung mitochondria whereas com-
plex I is the major source in the brain (Turrens and Boveris,
1980; Turrens et al., 1982; Barja and Herrero, 1998; Turrens,
2003). In general, acute and chronic infusion of Ang II has
been shown to decrease expression of electron transport
chain proteins (Larkin et al., 2004). Excessive ROS produc-
tion due to Ang II can impair complex I and III activities,
increasing electron leakage (Prathapan et al., 2014). More
information is needed to delineate the role of RAS in the
modulation of complex III.
(iii) NADPH oxidase (NOX) family proteins: NOX is a fam-
ily of transmembrane proteins that may be source of ROS.
NADPH oxidase works as a nonspecific host defense sys-
tem by releasing large amounts of ROS during infections
(Thrasher et al., 1994). When cytoplasmic NADPH oxi-
dase is activated, it moves toward membrane-associated
cytochrome b558 to form a complex. Cytochrome b558 reg-
ulates the enzymatic activity of NADPH oxidase by transfer-
ring one electron to molecular oxygen, which gets reduced
to O·−2 (Bayraktutan et al., 1998). While neutrophil NADPH
oxidase produces ROS in bursts, vascular NADPH oxidases
produce low levels of O·−2 continuously (Cai et al., 2003).
NADPH-derived cytoplasmic ROS can mediate mtKATP
opening enabling K+ influx that produces membrane depo-
larization and alkalinization of the matrix (Di et al., 2007).
This matrix alkalization has been shown to increase H2O2 in
the presence of anmtKATP opener (Pain et al., 2000; Heinzel
et al., 2005; Andrukhiv et al., 2006; Daiber, 2010).
Location and expression level of the different NOX enzymes
determine their function. NOX1 is abundant in colon epithe-
lium and has been reported to play a role in host defense in
intestinal crypts and on luminal surface (Szanto et al., 2005).
NOX2 is expressed in granulocytes and monocyte/macrophages.
ROS generation through NOX2 activation has been shown to
play a role in killing microbes and inactivating microbial viru-
lent factors. The exact localization and level of expression of the
different NOX enzymes are still not completely sorted out yet.
NOX3 has been generally located in the cochlear and vestibular
sensory epithelia, and spiral ganglion. NOX4 has been shown to
be expressed in the kidney and suggested that it plays a role in
protection of the vasculature during inflammatory stress. ROS
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generation through NOX4 has also been shown to induce HIF-1α
transcription factors, which in turn leads to activation of ery-
thropoietin gene in the kidney (Bedard and Krause, 2007; Jung
et al., 2008; Schroder et al., 2012). NOX5 is expressed in vari-
ous tissues including spleen, lymph nodes, and vascular smooth
muscle cells (Bedard and Krause, 2007). NOX5 increases Jak2
phosphorylation, which increases vascular smooth muscle cell
(VSMC) proliferation in human coronary arteries, aorta, and
splenic vessels (Fulton, 2009).
NADPH oxidase is a major source of angiotensin II-induced
ROS generation. NOX1 appears to have various roles in VSMCs,
including Ang II-induced hypertrophy, serum-induced prolif-
eration, and basic fibroblast-induced growth factor migration
(Redmond and Cahill, 2012). It localizes in VSMCs from large
arteries (Nguyen Dinh et al., 2013). NOX1 is needed under vari-
ous physiologic conditions such as thrombin-induced migration,
endothelial cell proliferation, cell growth, and vessel formation
(Sunggip et al., 2013). Overproduction of O·−2 from NOX1 and
NOX 2 can cause renin release, smooth muscle cell proliferation,
and decreased NO·, all of which lead to endothelial dysfunction
and increased sympathetic tone that in turn cause hypertension
(Takac et al., 2012). Ang II can signal via phospholipase D and this
pathway may cause VSMC proliferation and contractility through
NADPH oxidase (Touyz and Berry, 2002). NOX1distributes in the
plasma membrane, primarily generating O·−2 anions (Dikalova
et al., 2005; Valente et al., 2012). Ang II activates NOX1 via
NOX1-AT1R interaction. This is supported by a study showing
that continuous infusion of Ang II was correlated with increased
NOX1 mRNA expression (Valente et al., 2012). NOX1 functions
are mostly growth-promoting being highly expressed in prolifer-
ating cells. It activates VEGF andmatrix metalloproteinase, which
promote angiogenesis (Lassegue et al., 2001; Wilkinson-Berka
et al., 2014). NOX1 is also responsible for O·−2 generation and is
implicated in many pathological conditions including atheroscle-
rosis, diabetes and hypertension (Chose et al., 2008; Briones et al.,
2011).
NOX4 is found in subcellular compartments such as the
nucleus, endoplasmic reticulum, and mitochondria (Wingler
et al., 2001; Briones et al., 2011). Unlike NOX1, NOX4 typi-
cally generates H2O2 (Briones et al., 2011; Valente et al., 2012).
NOX4 serves as an oxygen sensor and regulates erythropoietin
synthesis in the kidneys (Geiszt et al., 2000). In VSMCs, NOX4
is found in focal adhesions and shown to maintain differentiation
of cells whereas NOX 1 induces growth and proliferation. This
phenomenon was seen in multiple tissues. For example, in coro-
nary arteries, NOX4 expression was correlated with α-actin levels
in osteoclasts, and over-expressed NOX4 was associated with
increased osteoclast markers. NOX4 is important for maintain-
ing physiologic function of many tissues (Clempus et al., 2007).
NOX4 is not up- but instead down-regulated when treated with
Ang II (Lassegue et al., 2001; Wingler et al., 2001). Both NOX2
and NOX4 are present in the aortic vascular smooth muscle.
When infused with Ang II, NOX2 knock-out mice did not have
significant hypertrophy. Therefore, NOX2 was deemed essential
for Ang II-induced cardiac hypertrophy and NOX 4 did not seem
to play a big role in Ang II-induced cardiac pathologies (Byrne
et al., 2003). This argument is supported bymany research groups
that studied Ang II’s effects on ROS generation. Interestingly,
Ang II doubled the ratio of O·−2 to H2O2 ratio in quiescent
cells and almost quadrupled it in proliferating cells. In addition,
NOX4 is a source of H2O2in a variety of vascular cells includ-
ing fibroblasts, endothelium, and smooth muscles. This constant
generation of H2O2 might be essential to maintaining cell func-
tions in angiogenesis during wound healing (Dikalov et al., 2008).
Increased NOX4 expression is essential in tissue survival during
ischemic stress, tissue remodeling, and regulation of glutathione.
Interestingly, NOX4 has been implicated in cardiac hypertrophy,
interstitial fibrosis, and apoptosis in cardiac muscle; however, car-
diac function was still maintained (Zhang et al., 2010; Brewer
et al., 2011; Schroder et al., 2012; Sunggip et al., 2013). Though
some studies show NOX4 playing a role in pathophysiology, the
great majority shows that the physiological role of this enzyme is
more relevant.
ROLE OF RAS IN ROS SCAVENGING
To maintain ROS balance, the production of ROS has to be
matched with a ROS scavenging mechanisms (Figure 1). MnSOD
in the mitochondrial matrix converts O·−2 to H2O2, which can
diffuse across membranes. O·−2 dismutation to H2O2 is important
for signaling and avoiding oxidative damage, in case of oxidative
stress (Kang and Pervaiz, 2012). H2O2 is scavenged by glutathione
peroxidase (GPX) and peroxiredoxin (PRX). NADPH gener-
ated frommitochondrial transhydrogenase (Hoek and Rydstrom,
1988; Jackson, 2003) is the main electron of the GSH and Trx
systems (Nickel et al., 2014). Under normal function, GSH and
Trx mitochondrial systems are mainly responsible for offset-
ting most of the ROS produced by the respiratory chain, espe-
cially under state 3 respiration when electron flow is maximal
(Aon et al., 2012). Other antioxidants localized to cytoplas-
mic and intermembrane space include Copper-Zinc superoxide
dismutase (Cu-ZnSOD) and catalase (Aon et al., 2012). ROS
can mediate increased expression of antioxidant enzymes via
activation of the Nrf2-antioxidant response element signaling
pathway (Nguyen et al., 2009). ROS-activated Nrf2 increases
ARE-mediated gene expression, which includes many antioxi-
dants such as glutathione S-transferase, quinine reductase, and
heme oxygenase 1 (Bergelson et al., 1994; Alam et al., 1999).
Levels of antioxidants are often decreased in disease states or
under oxidative stress. For example, diabetes and insulin resis-
tance are correlated with decreased antioxidant capacity due to
decreased SOD and glutathione reductase activities (Aon et al.,
2012). Under normal conditions, however, antioxidant enzymes
play a major role in scavenging ROS generated from various
sources like NADPH oxidase, NOS, xanthine oxidase, and mito-
chondrial electron transport chain enzymes.
Angiotensin II has been implicated in decreasing the activ-
ity of scavenging enzymes, thereby leading to detrimental levels
of ROS. Ethanol ingestion is associated with oxidative stress and
decreased GSH levels via activation of the RAS.When ethanol-fed
rats were treated with the AT1R blocker losartan, GSH levels were
maintained (Bechara et al., 2005). SOD are also targets of Ang
II. Mammals possess three SOD isoforms, Cu-Zn SOD (SOD1),
Mn SOD (SOD2), and extracellular SOD (SOD3) located in the
cytoplasm, mitochondria and the extracellular space, respectively
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(Rodriguez-Iturbe et al., 2007). SOD1 is a major defense sys-
tem against Ang II-triggered ROS in the kidneys. SOD1 knockout
mice showed 4-fold increase in afferent arteriolar O·−2 levels when
treated with Ang II (Carlstrom et al., 2010). In addition, in coro-
nary artery disease patients, SOD3 levels were severely reduced
in the human arterial walls and this decrease was associated with
oxidative stress and reduced NO· bioavailability; these conditions
were shown to contribute to the pathophysiology of the disease
(Landmesser et al., 2007). When treated with the AT1R blocker
losartan, an increase in NO· bioavailability and SOD3 activity
were seen. A more than 200% increase in SOD3 activity was asso-
ciated with reduced oxidative stress and improved endothelial
function (Hornig et al., 2001). Catalase activity was diminished
in Ang II-stimulated cardiomyocytes whereas ROS-elicited by
Ang II in mesangial cells implied reduced catalase transcription
(Venkatesan et al., 2007; Murtaza et al., 2008; Tan et al., 2008).
Reduced catalase mRNA expression and protein levels were noted
with Ang II treatment of VSMCs (Xiong et al., 2010). There is
also some evidence about the modulation of the Trx system by
the RAS system; ACE inhibitors have been shown to improve
myocarditis via a mechanism involving the Trx system (Tanito
et al., 2004; Touyz, 2004). The RAS not only contributes directly
to ROS generation, but also it affects indirectly the redox balance
via modulation of various antioxidant enzymes. Treatment meth-
ods involving inhibition of RAS enzymes, specifically Ang II type
1 receptor blocker, may be crucial in impeding pathophysiological
behavior.
ROS AS SIGNALING MOLECULES
Angiotensin II interacts with various tissues including vascular,
renal, and neuronal to induce numerous physiologic signaling
cascades and functions. Griendling et al. discussed the role of
Ang II in modulating growth-related signaling pathways via ROS
signaling (Griendling and Ushio-Fukai, 2000). ROS-mediated
oxidation can alter gene expression thorough signaling cascades
induction, or interaction with transcription factors. H2O2 can
reversibly inhibit tyrosine phosphatase PTP1B, a regulator of the
insulin signaling pathway (Apel and Hirt, 2004; Combs, 2010).
Recent research focuses on PTP1B inhibitors as potential thera-
peutic treatment for type 2 diabetes and obesity (Thareja et al.,
2012). ROS also play a role in tyrosine phosphorylation as shown
in platelet-derived growth factor where a transient increase in
ROS inactivated tyrosine phosphatase (Finkel, 1998). Nontoxic
amounts of H2O2 administered extracellularly have been shown
to stimulate mitogen activated protein kinase (MAPK), that
directly affects the inflammatory response, cell proliferation, dif-
ferentiation, and survival in response to extracellular stimuli
(Stevenson et al., 1994; Arbabi and Maier, 2002). Exogenous
H2O2 has also been shown to activate JNK, (Finkel, 1998) p38,
(Hensley et al., 2000) and NF-KB, a protein complex that induces
expression of protective genes during inflammation and infection
(Baeuerle and Henkel, 1994).
ROS participate in the host innate immune response. Immune
cells undergo respiratory burst, producing high levels of free oxy-
gen radicals during infection, a response that results toxic to
pathogens (Spooner and Yilmaz, 2011).When a pathogen invades
a cell, Leucine-Rich Repeat-containing family member receptor,
NLRX1, moves to the mitochondria to stimulate the electron
transport chain and initiate ROS production (Arnoult et al.,
2009). Since ROS are produced by NADPH oxidases in mature
phagocytic cells, many bacteria, like Francisellatularensis, interfere
with NADPH oxidase assembly (Cirillo et al., 2009). Oxidative
burst within macrophages has been shown to decrease urogen-
ital infections associated with pathogen Chlamydia trachomatis
(Boncompain et al., 2010).
In addition to fighting infections, ROS have also been impli-
cated in cancer therapy since increased ROS levels may be lethal
for tumor cells triggering apoptosis. Direct exposure of cancer
cells to ROS generating agents like arsenic trioxide, or alterna-
tively inhibiting antioxidant enzymes with2-methoxyestradiol, a
SOD inhibitor, may trigger apoptosis in human leukemia (Zhou
et al., 2003; Pelicano et al., 2004).
Overall, available evidence indicates that controlled levels of
ROS represent effective signaling molecules, intervening in differ-
ent cellular processes as diverse as communication, inflammation,
immunity, and as therapeutic cancer agents. The role of RAS
induced ROS in signaling pathways is discussed next.
EPIDERMAL GROWTH FACTOR (EGF) AND EXTRACELLULAR
SIGNAL-REGULATED KINASE 1/2 (ERK1/2)
EGF is required for Ang II effects on various tyrosine kinases,
and its activation is initiated by NOX-induced ROS (Eguchi
et al., 1998; Griendling and Ushio-Fukai, 2000; Ushio-Fukai et al.,
2001). C-Src, a tyrosine kinase activated by Ang II, promotes mul-
tiple signaling events including various MAPKs. Ang II-induced
activation of c-Src is redox-sensitive since its stimulation is inhib-
ited by antioxidants (Abe et al., 1997; Ushio-Fukai et al., 2001).
EGF receptor activation is needed for Ang II action on ERK1/2, a
type of MAPK (Eguchi et al., 1996; Liao et al., 1997; Griendling
and Ushio-Fukai, 2000). ERK1/2 has an important role in cell
adhesion, cell cycle progression, migration, survival, differentia-
tion, metabolism, and proliferation (Roskoski, 2012). Activation
of ERK1/2 is said to be redox-sensitive or redox-insensitive in
some studies (Sundaresan et al., 1995; Viedt et al., 2000).
MAPK AND ADENILATE KINASE (Akt)
MAPKs control various cellular activities like growth, apoptosis,
and stress signals. Four main MAPKs are ERK1/2, c-Jun N termi-
nal kinase (JNK), p38MAPKs, and big MAPK-1. Ang II can acti-
vate JNK, ERK1/2, and p38MAPK. Though there is an ambiguity
as to whether ERK 1/2 is redox-sensitive or not, p38MAPK and
JNK have been shown to be redox-sensitive when activated by Ang
II. Ang II triggers ROS generation through NADPH oxidase acti-
vation, followed by JNK and p39MAPK stimulation (Griendling
and Ushio-Fukai, 2000; Viedt et al., 2000). In VSMCs, Ang II acti-
vates Akt, a serine threonine kinase that plays a role in cell survival
and protein synthesis. NADPH-derived ROS induces Akt which
is associated with heat shock protein 27, also activated by H2O2
(Konishi et al., 1997; Coffer et al., 1998; Ushio-Fukai et al., 1999;
Griendling and Ushio-Fukai, 2000).
NITRIC OXIDE SYNTHASE (NOS)
NOS is another enzyme capable of producing O·−2 using tetrahy-
drobiopterin as a cofactor. Superoxide generated from NADPH
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oxidases can give rise to peroxynitrite (ONOO−) (Figure 1).
ONOO− contributes to oxidation of tetrahydrobiopterin, lead-
ing to NOS uncoupling and more O·−2 generation (Landmesser
et al., 2003). A mitochondrial variant of NOS (mtNOS) can
generate nitric oxide (NO·), a reactive nitrogen species (RNS).
Mitochondrial respiration can be partially inhibited by NO·,
through inactivation of cytochrome c oxidase from complex IV
that can lead to increased ROS production and a vicious cycle
of mitochondrial damage by ROS excess (Kang and Pervaiz,
2012). Excess NO· can react with O·−2 to form the highly
reactive ONOO− which, like O·−2 , is unable to permeate the
mitochondrial membrane, can cause oxidative damage, nitra-
tion and nitrosation (Squadrito and Pryor, 1995; Kang and
Pervaiz, 2012). MnSOD can be nitrated by ONOO−, decreas-
ing its activity (Quijano et al., 2001). Ang II-treated endothe-
lial cells released more H2O2, and exhibited mitochondrial loss
of membrane potential, respiration impairment, and decreased
GSH and NO· formation (Doughan et al., 2008; Daiber, 2010).
The reduction of dihydrobiopterin to tetrahydrobiopterin is cat-
alyzed by dihydrofolate kinase. Tetrahydrobiopterin is needed
by eNOS for basal NO· production. Ang II can lead to eNOS
uncoupling via H2O2 production in a NOX-dependent man-
ner. This results in down-regulation of dihydrobiopterin kinase
and diminished tetrahydrobiopterin cofactor and nNOS uncou-
pling. Dysfunctional eNOS results in decreased NO· bioavail-
ability (Cai and Harrison, 2000; Sunggip et al., 2013). Ang
II-induced O·−2 can react with endothelial NO· produced by
eNOS, decreasing its concentration even more. Loss of NO·
contributes to endothelial dysfunction initiating atherosclero-
sis (Nickenig and Harrison, 2002). In addition, expression of
inflammatory molecules like MCP-1 and VCAM-1 appears to
be indirectly regulated by Ang II, accelerating atherosclerosis
(Nickenig and Harrison, 2002). Angiotensin II-induced phos-
phorylation of various kinases activates NOX and increases ROS
generation.
XANTHINE OXIDASE (XO)
XO is a major source of ROS. Xanthine oxidoreductase (XOR)
degrades purines to generate uric acid. XOR is transcribed as
xanthine dehydrogenase, which is converted to XO after oxida-
tion of cysteine residues or proteolysis (Waud and Rajagopalan,
1976; Amaya et al., 1990; Kelley et al., 2010). XO generates both
O·−2 and H2O2, the latter in greater amounts under low O2
and pH, e.g., inflammation, ischemia. Higher O·−2 levels can be
detected under low xanthine concentrations, and high O2 ten-
sions (Kelley et al., 2010). Landmesser et al. showed that Ang
II administration elevates XO through ROS from NADPH oxi-
dase. NADPH oxidase inhibition decreased XO and O·−2 levels
suggesting that Ang II stimulation of NOX proteins is needed
for XO stimulation. Additionally, XO inhibitors like oxypuri-
nol and tungsten markedly reduced Ang II-induced endothelial
O·−2 , in agreement with the idea that Ang II stimulates XO.
Furthermore, losartan (AT1R blocker) treatment decreased the
endothelial levels of both XO and O·−2 . Patients with coronary
disease treated with AT1R blocker for 4 weeks displayed reduced
endothelial XO activation compared to the placebo (Landmesser
et al., 2007).
OTHER ENZYMES
Other enzymes such as pyruvate dehydrogenase, α-ketoglutarate
dehydrogenase, glycerol-3-phosphate dehydrogenase, and from
fatty acid β oxidation can also contribute to ROS generation
(Kang and Pervaiz, 2012). Ang II can modulate the activity of
these various enzymes. For instance, many studies have shown
effects of Ang II on fatty acid oxidation and nonalcoholic fatty
liver disease (Kurita et al., 2008; Toblli et al., 2008). Increased Ang
II levels cause mitochondrial oxidative damage, which leads to
impairment of beta oxidation causing hepatic steatosis. Treatment
with AT1R blockers like valsartan produced substantial improve-
ment of mitochondrial abnormalities (Monteiro et al., 2005). The
mechanism by which fatty acid oxidation appears to be mediated
by ROS generated from NADPH oxidase as well as decreased Cu,
Zn SOD activity (Wei et al., 2009). Ang II has also been shown to
promote pyruvate dehydrogenase complex acetylation, leading to
decreased glucose oxidation (Mori et al., 2013). α-ketoglutarate
dehydrogenase activity was shown to be increased by Ang II
treatment. Increased cytoplasmic and mitochondrial free Ca+2
levels are associated with hepatic stimulation via Ang II. Since
α-ketoglutarate dehydrogenase function is positively stimulated
by Ca+2, its activity is indirectly influenced by Ang II (Exton,
1985; Williamson et al., 1985; Rashed et al., 1988).
Together, the evidence available indicates that RAS can induce
ROS generation through direct—influencing various signaling
pathways, as well as indirect—modulating activities of antioxi-
dant enzymes, mechanisms.
AGING, MITOCHONDRIA AND RAS ASSOCIATED PATHOLOGY
Aging is associated with the accumulation of various deleterious
changes in cells. According to the free radical and mitochondrial
theory of aging, mitochondria initiate most of the deleterious
changes in aging and govern life span (Harman, 1956, 2006;
Cadenas and Davies, 2000; Cadenas, 2004). Three key mito-
chondrial functions that become dysregulated with aging are: (1)
ROS production, (2) ATP synthesis, and (3) apoptosis (Conley
et al., 2007). As proposed by the mitochondrial theory of aging,
increased mitochondrial ROS generation precipitates mitochon-
drial DNA damage and mutations, which in turn leads to failed
oxidative phosphorylation and diminished ADP/ATP reservoir
(Harman, 1956, 2006), ultimately contributing to mitochondrial
deterioration and activation of cell death pathways (Echtay et al.,
2002; Dirks et al., 2006; Skulachev, 2006; Conley et al., 2007;
Pandur et al., 2014). Moreover, mitochondrial morphodynamics
through fusion and fission can also be altered with aging could
potentially lead to their dysfunction (Bleazard et al., 1999; Chen
et al., 2003; Yu et al., 2012). Chronically activated ROS has been
implicated in mitochondrial energetic impairment along with the
development and progression of a host of aging-related condi-
tions including atherosclerosis, myocardial hypertrophy, vascular
dysfunction, hypertension (Heymes et al., 1998;Wang et al., 2003;
Kimura et al., 2005; Doughan et al., 2008; Fukai, 2009; Min et al.,
2009; Widder et al., 2009), type 2 diabetes, frailty, heart failure,
neurodegeneration (including Alzheimer’s disease, Horan et al.,
2012), and sarcopenia (Ballinger et al., 1994; Wallace, 2001, 2005,
2010, 2011; Loeb et al., 2005; Conley et al., 2007; Moore et al.,
2010). Clinically, the onset of this mitochondrial failure is difficult
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to estimate, however, the accumulation of damaged mitochon-
dria typically appears in humans by mid to late seventies and once
established is thought to be irreversible (Aiken et al., 2002; Herbst
et al., 2007). Recently, several studies have shed light on early
mitochondrial changes in healthy subjects that predate the accu-
mulation of damaged mitochondria by almost a decade. These
studies have demonstrated that increased uncoupling leads to a
reduction in mitochondrial efficiency in otherwise healthy people
in their sixties (Greco et al., 2003; Hutter et al., 2004; Bua et al.,
2006; Mogensen et al., 2006; Amara et al., 2007).
The major mechanism by which dysfunction occurs is
via mtDNA mutations. Unlike nuclear genome, mitochondrial
genome is circular, and is not condensed around histones or
packed tightly. This makes it less protected and more easily
damageable than nuclear DNA (nDNA) (Croteau et al., 1999).
mtDNA damage is mostly attributed to ROS. AngII can stimu-
late mitochondrial ROS production via activation of cytoplasmic
NOX-derived O·−2 and through direct effects on mitochondria
as well. Administration of antioxidants inhibited Ang II effects
on AP-1 signaling pathway (Puri et al., 1995; Xia et al., 1998;
de Cavanagh et al., 2007). Further evidence in support of Ang
II action on mitochondria is given by research showing AT2R
co-localization with this organelle likely in inner membrane, in
various tissues. Ang II and AT2R are likely generally present in the
inner membrane of mitochondria (Inagami, 2011). Ang II stim-
ulates production of NO· via activation of calcium/calmodulin-
dependent eNOS, including mRNA and protein expression levels
(Brown, 1999; Yan et al., 2003). mtDNA codes for critical pro-
teins participating in oxidative phosphorylation (Croteau et al.,
1999). In addition, mtDNA has less repair mechanisms compared
to nDNA; for example, mitochondria lack nucleotide excision
repair mechanisms (Larsen et al., 2005). mtDNA mutation rate
is shown to increase with age, affecting liver, skeletal muscles, and
cardiac muscles (Katayama et al., 1991; Corral-Debrinski et al.,
1992; Marin-Garcia et al., 2002; Druzhyna et al., 2008). Excess
ROS generation may overwhelm antioxidant enzymes, thereby
preventing themitochondria from protecting themselves (Golden
and Melov, 2001). With chronic exposure to elevated ROS and
decline in repair mechanisms, mtDNA mutations accumulate
during aging (Lin and Beal, 2006). Under RAS over-activation-
as seen in diabetes, hypertension and aging- Ang II induced ROS
plays a significant role in tissue damage. Ang II induced mtROS
generation has been implicated in atherosclerotic lesions and
impairment of cardiac respiration and TCA cycle function leading
to disease (Pueyo et al., 2000; de Cavanagh et al., 2007).
In cardiovascular tissue, mitochondrial ROS contribute to
senescence of endothelial cells and chronic low-grade vascular
inflammation (Ungvari et al., 2007). These endothelial cells can
contribute to atherosclerosis by suppressing regeneration and
angiogenesis of endothelium in the vascular wall leading to car-
diovascular aging (Dai et al., 2012) and the development of
hypertension (Heymes et al., 2003; Shiomi et al., 2004; Wang
et al., 2010; Sugamura and Keaney, 2011; Dikalov and Ungvari,
2013).
Development and progression of several neurodegenerative
disorders has also been linked to mitochondrial dysfunction
(Beal, 2007). A significant decrease in mitochondrial coupling
efficiency in primary hippocampal neurons, reduced steady state
basal respiration, and decreased ATP turnover were noted in
several neurodegenerative disorders (Horan et al., 2012). In
Alzheimer’s disease, several studies have demonstrated that oxida-
tive damage appears to increase development of intracellular Aβ
plaques. ROS activation of c-Jun N terminal kinase and p38
mitogen activated protein kinase lead to increased activity of β
secretase, causing increased Aβ levels (Nishida et al., 2006; Beal,
2007). Parkinson’s disease is caused by a recessive mutation of DJ1
that leads to hypersensitivity to MPTP and oxidative stress since
DJ1 protects against oxidative stress-induced cell death. Studies
show that treatment with SOD1 and vitamin E decrease degener-
ation of dopaminergic neurons (Bonifati et al., 2003; Kim et al.,
2005; Wang et al., 2006a). Huntington’s disease (HD) is also asso-
ciated with oxidative stress since reduced activity of Complex
II and III is seen in basal ganglia and cortex. In addition, HD
patients show decreased PGC1α, which suppresses ROS by acti-
vating ROS scavenging enzymes (St-Pierre et al., 2006; Weydt
et al., 2006; Beal, 2007). ROS are implicated not only in neu-
rodegenerative disorders but also in various other diseases like
age-related musculoskeletal disorders. In sarcopenia, a disease
characterized by reduced skeletal muscle mass with aging, elec-
tron transport system abnormalities were seen in muscle fibers
with “ragged red” phenotype and these changes were associ-
ated with loss of muscle mass (Bua et al., 2002). Patients with
Type 2 diabetes show decreased antioxidant capacity and pos-
sibly an increase in ROS generation by leukocytes (Mohanty
et al., 2000). Studies show increased expression of ROS markers
in pancreatic islet cells under diabetic conditions. Furthermore,
β cells are much more sensitive to ROS due to decreased antioxi-
dant capacity. Chronic hyperglycemia increases ROS levels while
decreasing binding of the transcription factors PDX-1 and Maf-A
from pancreas that exacerbates suppression of insulin synthe-
sis and release. In addition, treatment with antioxidants such
as N-acetyl-L-cysteine and taurine, diminished insulin resistance
due to hyperglycemia (Kaneto et al., 2010).
The overlap between age related changes in RAS and mito-
chondria and the implications of this overlap on age-related
diseases are quite complex. Studies shows that Ang II contributes
to plaque rupture by initiation of VSMC apoptosis, which could
be prevented by AT1R blockers (Lemay et al., 2000). Ang II
induces metalloproteinase activity, which is involved in colla-
gen breakdown and matrix degradation, indirectly through ROS
(Shah and Galis, 2001; Nickenig and Harrison, 2002). Ang II
can induce interleukin-6 (IL6), leukemia inhibitory factor, and
cardiotrophin-1 in cardiac fibroblasts (Sano et al., 2001). IL-6
is an inflammatory marker and a high level of which is associ-
ated with mortality due to increased progression of cardiovas-
cular disease (Volpato et al., 2001). Leukemia inhibitory factor
is a key player in cardiac hypertrophy (Kodama et al., 1997).
Cardiotrophin-1 plays a role in heart failure since it can induce
ventricular remodeling by activating cardiomyocyte hypertrophy
and collagen synthesis (Calabro et al., 2009).
Many studies highlighted the role that RAS plays in hyper-
tension and cardiovascular disease (Marchesi et al., 2008). By
activating local mediators, like vascular endothelial growth factor
(VEGF) and prostaglandins, such as leukotriene C4, PGE2, and
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PGI2, Ang II plays a critical role in regulating vascular permeabil-
ity during hypertension (Harris et al., 2004). Ang II-stimulated
release of these local factors in VSMCs leads to angiogenesis,
vascular permeability, and inflammation. In particular, studies
have shown that AT1R activation causes VEGF secretion (Suzuki
et al., 2003). Hypertension is a condition that results from ROS
of vascular origin produced by elevated levels of Ang II. Chronic
administration of Ang II in mice, triggered elevated O·−2 from
mitochondria as compared to controls (Widder et al., 2009). O·−2
and H2O2 produced due to elevated Ang II can carry out various
actions in VSMCs—phosphorylation of MAP kinases, induction
of proto-oncogenes, and activation of AP-1; H2O2 can induce
PDGF stimulation of STATS. All these signaling events contribute
to vascular wall remodeling and thickening seen in hyperten-
sion (Touyz, 2000). Ang II via AT1R also affects brain tissue by
increasing neuronal firing rate and activity. In neurons, NADPH
oxidase-derived ROS produced due to Ang II signaling increase
intracellular Ca+2 concentration (Wang et al., 2006b), which in
turn can stimulate mitochondrial O·−2 stimulates mitochondrial
superoxide generation (Hongpaisan et al., 2004). In rostral ven-
trolateral medulla, these effects may influence blood pressure,
causing baroreflex abnormalities in chronic hypertension (Nozoe
et al., 2008).
RAS has been implicated in many pathological conditions.
Ang II can precipitate mild to severe mitochondrial dysfunc-
tion in addition to ROS generation. Amelioration of age-related
renal mitochondrial dysfunction under hypertensive conditions,
and ischemic injury, has been described in patients treated with
angiotensin receptor blockers (Doughan et al., 2008). Losartan
treatment prevents mitochondrial dysfunction and structural
changes in the kidney while up regulating antioxidant enzymes,
maintaining GSH and MnSOD levels, and attenuating uncou-
pling proteins. These effects were not apparent when patients
were treated with a Ca2+ channel blocker allowing to conclude
that Ang II must play a role in mitochondrial dysfunction (de
Cavanagh et al., 2006).
Since Ang II is linked to NOX, Wosniak et al. (2009) exam-
ined the effects of mild mitochondrial uncoupling and Ang II
stimulation of NOX isoform in VSMCs. Ethidium bromide was
used to induce mild mitochondrial stress, which the investiga-
tors described as “neither rapidly lethal nor promoting profound
redox derangements” (Wosniak et al., 2009). Results showed that
Ang II-induced NOX activation can be completely eliminated
with mild mitochondrial uncoupling. Ang II up regulates NOX
1 expression and down regulates NOX4 expression and with
mild mitochondrial dysfunction there was a decrease in NOX1
and increase in NOX4. Therefore, these authors concluded that
functional mitochondria are required for Ang II-induced NOX
activation. Wosniak et al. also noted that mitochondrial func-
tion influences activation of growth factor receptors involved in
NOX signaling (Wosniak et al., 2009). In addition, when Ang II
was administered, increased mtDNA damage was only observed
in those cells that had existing dysfunctional mitochondria. Cells
with functional mitochondria did not show any markers of
mtDNA damage. The researchers speculated that mitochondria
might be acting as a switch between normal to pathological
effects of Ang II (Wosniak et al., 2009). The relationship between
angiotensin-related mitochondrial ROS and NADPH oxidase is
still a novel area of research that can potentially provide insight
into pathophysiology of many diseases and may pave the way for
new therapeutic approaches.
THE USE OF ANGIOTENSIN RECEPTOR BLOCKERS (ARBs) IN
MITOCHONDRIAL DYSFUNCTION
Elevated Ang II produces increased levels of ROS (by activating
NADPH oxidase and various other enzymes) that contribute to
various pathological conditions. AT1R blockade decreases RAS-
mediated activation of NADPH oxidase and oxidative stress,
leading to reduced left ventricular fibrosis and mitochondrial
remodeling (Whaley-Connell et al., 2008). Losartan treatment
also reverses left ventricular hypertrophy, reduces fibrosis, ulti-
mately causing an overall improvement of cardiac function
(Khaper and Singal, 2001). Various studies have shown a
lower rate of mortality from cardiovascular disease in patients
treated with angiotensin receptor antagonists. Beneficial effects
of angiotensin receptor blockers include lowered cerebral lesion
incidence, reduced cardiac hypertrophy, and reduced glomeru-
losclerosis. Eprosartan was shown to be effective in prevent-
ing cardiac remodeling, renal failure, and decreasing mortality
(Takemori et al., 2005). Interestingly, insulin treatment induces
AT1R overexpression, and in diabetics, ARBs have been shown
to effectively preserve renal function and reduce cardiovascular
endpoints (Nickenig et al., 1998; Nickenig, 2004). ARBs reduces
Ang-II induced lipolysis and adipocyte dysfunction (Takemori
et al., 2013). Contrary to AT1R, the effects of AT2R are considered
protective. ARBs may increase activation of AT2 receptor aug-
menting end-organ protection (Carey et al., 2000; Unger, 2002).
More research on ARBs and activation of AT2 receptormight yield
promising results in treating various pathological conditions.
AngII receptor blockers have several features in common:
high affinity for AT1R and almost no affinity for AT2 receptors;
high protein binding capacity behaving as competitive inhibitors
with slow dissociation (Burnier, 2001). There are six common
types of ARBs used currently as treatment for hypertension—
losartan, valsartan, candesartan cilexetil, irbesartan, eprosartan,
and telmisartan. These ARBs have been shown to protect against
various disease states. For example, in rats withmyocardial infarc-
tion, losartan improves function of several antioxidant enzymes,
significantly reducing oxidative stress. In particular, losartan
increases the activity of GSH peroxidase (Khaper and Singal,
2001) while decreasing levels of vascular O·−2 due to its antagonist
activity on AT1 receptors (Kurz et al., 1999). It also restores NO·
synthesis and availability playing its role as an antihypertensive
drug protecting endothelial cells (Qadri et al., 2001). Valsartan is
effective in improving heart mitochondrial function under acute
ischemia (Monteiro et al., 2005). Long-term treatment of rabbit
heart with valsartan, after infarction, showed reduced lipid per-
oxide levels; an improvement in postinfarct ventricular remod-
eling and coronary endothelial dysfunction was also seen (Kuno
et al., 2002). In diabetic patients, candesartan cilexetil has been
shown to improve pancreatic β cell function (Qadri et al., 2001)
and irbesartan was effective against postprandial hyperglycemia
and hypertriglyceridemia on endothelial function (Ceriello et al.,
2005). Telmisartan can inhibit apoptosis, oxidative stress, and
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neuro-inflammation in addition to its antihypertensive functions
(Beckman et al., 1990; Butler et al., 2003; Monteiro et al., 2005;
Shao et al., 2006). In hypertensive patients, ARBs were shown to
improve normal retinal perfusion and endothelium-dependent
vasodilation in coronary and renal circulation (Delles et al.,
2004). In addition, ARBs have been associated with a reduction
in inflammatory markers. This is of particular importance since
low grade chronic inflammation is associated with many neu-
rodegenerative diseases like Alzheimer’s and Parkinson’s diseases,
amyotrophic lateral sclerosis, multiple sclerosis, Huntington’s dis-
ease and frailty (Tracy, 2003; Gao and Hong, 2008; Holmes et al.,
2009). ARBs are also able to reverse early myocardial impairment
(Cadeddu et al., 2010), improve insulin sensitivity, decrease inci-
dence of type 2 diabetes (Saitoh et al., 2009) and prevent renal
fibrosis (Shao et al., 2006).
PROSPECTIVE
Mitochondrial dysfunction and oxidative stress underlie
many pathologies and constitute primary theories of aging.
Understanding how age-related mitochondrial dysfunction
might be mitigated or exacerbated is critical to advancing this
research field. The RAS is currently regarded as a physiological
system of vital importance because of its links to both mitochon-
drial function/dysfunction and a host of age-related diseases.
Although many prior studies have advanced our understanding
in each of these aging-relevant biological systems, the progress
in delineating the molecular mechanisms involved has been
rather slow. Given the availability of selective, and relatively
safe blockers of RAS, studies focusing on the interface between
mitochondria, RAS, and aging may prove to be very important in
clinical translation of research.
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